Janux Therapeutics, Inc. - Common Stock (JANX) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2021 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
JANX on Nasdaq
Shares outstanding
60,117,449
Price per share
$13.80
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
62,143,542
Total reported value
$857,606,904
% of total 13F portfolios
0%
Share change
-2,664,353
Value change
-$104,019,467
Number of holders
171
Price from insider filings
$13.80
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Janux Therapeutics, Inc. - Common Stock (JANX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 20% $383,922,060 11,971,377 RA Capital Management, L.P. 06 Mar 2025
JANUS HENDERSON GROUP PLC 8.9% -11% $73,836,251 -$9,432,245 5,350,453 -11% JANUS HENDERSON GROUP PLC 31 Dec 2025
STATE STREET CORP 6.4% $53,184,524 3,853,951 STATE STREET CORPORATION 31 Dec 2025
FMR LLC 5.8% $48,484,949 3,512,384 FMR LLC 31 Dec 2025
BlackRock, Inc. 5.7% $77,284,838 3,345,664 BlackRock, Inc. 30 Jun 2025
Prosight Management, LP 5.3% $43,569,636 3,157,220 W. Lawrence Hawkins 03 Feb 2026
Paradigm Biocapital Advisors LP 4.9% -18% $73,444,489 -$14,982,559 2,920,258 -17% Paradigm BioCapital Advisors LP 30 Jun 2025
Adage Capital Management, L.P. 4.3% -21% $63,503,750 -$13,499,262 2,525,000 -18% Adage Capital Management, L.P. 30 Jun 2025

As of 31 Dec 2025, 171 institutional investors reported holding 62,143,542 shares of Janux Therapeutics, Inc. - Common Stock (JANX). This represents 103% of the company’s total 60,117,449 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Janux Therapeutics, Inc. - Common Stock (JANX) together control 86% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 19% 11,189,693 0% 1.6% $154,417,763
JANUS HENDERSON GROUP PLC 8.9% 5,350,453 +14% 0.03% $73,850,341
BlackRock, Inc. 6.8% 4,080,200 +9.4% 0% $56,306,760
STATE STREET CORP 6.4% 3,853,951 +104% 0% $53,184,524
FMR LLC 5.8% 3,512,384 -61% 0% $48,470,898
VANGUARD GROUP INC 4.8% 2,906,386 +20% 0% $40,108,126
Prosight Management, LP 4% 2,392,523 +176% 6.8% $33,016,817
ORBIMED ADVISORS LLC 3.3% 1,954,426 +11% 0.58% $26,971,079
TCG Crossover Management, LLC 3% 1,789,617 0.82% $24,696,715
WELLINGTON MANAGEMENT GROUP LLP 2.7% 1,610,186 +130% 0% $22,220,567
Alyeska Investment Group, L.P. 2.2% 1,301,089 +206% 0.05% $17,955,028
GEODE CAPITAL MANAGEMENT, LLC 1.9% 1,113,582 +2.7% 0% $15,370,581
CITADEL ADVISORS LLC 1.8% 1,104,144 +38% 0.01% $15,237,187
GOLDMAN SACHS GROUP INC 1.8% 1,073,656 +64% 0% $14,816,453
Woodline Partners LP 1.7% 1,027,221 +0.03% 0.05% $14,175,650
Logos Global Management LP 1.7% 1,000,000 +7% 0.92% $13,800,000
Point72 Asset Management, L.P. 1.6% 961,819 -44% 0.02% $13,273,102
READYSTATE ASSET MANAGEMENT LP 1.5% 885,895 -7.8% 0.54% $12,225,351
Balyasny Asset Management L.P. 1.5% 885,551 0.02% $12,220,604
PRICE T ROWE ASSOCIATES INC /MD/ 1.2% 744,466 -41% 0% $10,274,000
BANK OF AMERICA CORP /DE/ 1.2% 738,330 +50% 0% $10,188,954
Cormorant Asset Management, LP 1.1% 650,000 -24% 0.51% $8,970,000
MORGAN STANLEY 1% 618,385 +25% 0% $8,533,727
UBS Group AG 0.98% 590,060 +51% 0% $8,142,828
JANE STREET GROUP, LLC 0.9% 540,233 +564% 0.01% $7,455,216

Institutional Holders of Janux Therapeutics, Inc. - Common Stock (JANX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 62,143,542 $857,606,904 -$104,019,467 $13.80 171
2025 Q3 65,065,945 $1,590,036,358 -$3,819,977 $24.44 170
2025 Q2 65,389,958 $1,510,522,459 -$28,053,981 $23.10 169
2025 Q1 66,482,175 $1,805,570,973 -$17,647,630 $27.00 179
2024 Q4 64,089,510 $3,430,809,553 +$1,001,839,547 $53.54 213
2024 Q3 45,621,730 $2,072,353,785 +$42,332,014 $45.43 158
2024 Q2 44,723,442 $1,873,142,325 +$107,659,314 $41.89 153
2024 Q1 42,327,541 $1,593,608,078 +$334,250,630 $37.65 118
2023 Q4 33,501,695 $359,539,970 -$17,204,195 $10.73 64
2023 Q3 35,112,124 $353,984,587 +$45,518,472 $10.08 57
2023 Q2 30,508,831 $362,117,070 -$408,523 $11.87 54
2023 Q1 30,541,873 $369,527,936 +$18,629,245 $12.10 48
2022 Q4 28,954,042 $381,308,644 -$7,758,264 $13.17 49
2022 Q3 29,548,436 $400,093,845 +$8,918,649 $13.54 45
2022 Q2 28,911,820 $352,963,471 +$6,297,905 $12.21 43
2022 Q1 28,388,419 $407,113,023 +$11,406,319 $14.34 46
2021 Q4 27,496,946 $541,627,745 +$19,103,067 $19.73 46
2021 Q3 26,499,088 $571,208,440 +$35,499,490 $21.63 44
2021 Q2 24,743,225 $614,460,000 +$614,460,000 $24.95 29